Summary.-Sensitivity to human encephalitogenic factor (EF) Homologous serum from patients with carcinoma of the breast or lung with and without autologous blocking activity and serum from a healthy individual were tested against lymphocytes from patients with various tumour types with the MMI test. Of 11 patients tested in the absence of serum, 8 (73%) showed significant migration inhibition with EF, whilst serum from patients with carcinoma of the lung or breast with autologous blocking activity abolished migration inhibition with EF in all 8 individuals with the former and in 6 with the latter, regardless of the tumour type from which the lymphocytes under test were derived. Homologous serum from both a carcinoma of the lung and breast without autologous blocking activity did not abolish migration inhibition with EF, except with the latter in one patient with a carcinoma of the lung.
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A DELAYED hypersensitivity response to encephalitogenic factor (EF), a small polypeptide derived from the myelin sheath of human and animal brain tissue, has been reported in a number of human pathological conditions, notably in malignant disease. The nature and significance of such sensitivity in neoplastic disease is uncertain, though it seems possible that this represents immunological crossreactivity between EF and neoantigen(s) appearing on the tumour-cell surface. In support of this, Caspary and Field (1971) have shown that lymphocytes from cancer patients interact specifically with EF and 2 a basic protein extracted from human cancer tissue termed cancer basic protein (CaBP) in the macrophage electrophoretic mobility (MEM) test. Further investigations have shown the two proteins to be very similar chemically (Carnegie, Caspary and Field, 1973; Dickinson, Caspary and Field, 1973) and to be immunologically cross-reactive (Coates and Carnegie, 1975; McDermott, Caspary and Dickinson, 1974 ). An alternative explanation to account for the appearance of EF sensitivity in both malignant and non-malignant disease was proposed by Mitchell (1973) (Caspary and Field, 1971; Goldstone, Kerr and Irvine, 1973; Pritchard et al., 1973) ; moreover, the claim has been made that the MEM test can discrminate between patients with early and advanced cancer (Field and Caspary, 1972) . However, results with the macrophage migration inhibition (MMI) test are not so encouraging, with only about 70% of cancer patients tested showing a response to EF (Shelton, Potter and Carr, 1975; Singer et al., 1975; Light, Preece and Waldron, 1975 Moftp1ha,q migration inhibition test.-Twenty ml of venous blood was collected from each individual under study and 10 ml placed into a lithium heparin sample tube (Searle Diagnostics, Wycombe, England) and 10 ml into a plain glass tube. Lymphocytes were harvested from the heparinized blood by the Ficoll-Triosil technique of Pritchard et al. (1973) . Lymphocytes obtained in this way were washed x 3 in TC199 (Wellcome Reagents Ltd., Beckenham, England) and stored at 40C in TC199 containing 10% heatinactivated foetal calf serum (FCS) until use. Peritoneal exudate cells (PEC) were induced in Hartley guinea-pigs (200-400 g) by i.p. stimulation with 10 ml of liquid paraffin, and collected and processed as described previously (Rees and Potter, 1973 Serum inhibition of EF-mediated migration inhibition.-Ten ml of venous blood collected from each individual under test was allowed to clot at room temperature for 1 h and was centrifuged at 1500 g for 10 min. The serum was harvested from the tube and heat-inactivated at 56°C for 30 min. The effects of autologous serum drawn from the same patient, or homologous serum drawn from different patients with the same or different tumour types, upon EF-mediated migration inhibition were studied by including the serum under investigation in a duplicate set of wells at a 10% concentration with and without EF.
RESULTS

Sensitization to EF in cancer patients and controls
A total of 70 individuals with malignant disease were tested for sensitivity to EF with the MMI test. The results are shown in Table I and in Fig. 1 . A significant inhibition of macrophage migration (P<001) with EF was seen in 44 of these patients. Division of this group into 3 clinical stages (I-III) showed that the frequency of sensitivity to EF was about the same in all 3 (Table I) . Patients with non-malignant diseases were divided into individuals with chronic bronchitis, warts, multiple sclerosis, neurological conditions a.nd others. The results for 34 individuals tested with nonmalignant disease are shown in Table II and Fig. 2 . Significant migration inhibition with EF was seen in 11 of these patients, the highest frequency of sensitivity being observed in 9 patients with various neurological conditions, among whom 4 showed sensitivity, and the lowest frequency in a group of 6 individuals with simple epidermal warts, among whom one showed significant migration inhibition. Lymphocytes from 18 healthy individuals were also tested for sensitivity to EF with the MMI test. The results are shown in Table II and in Fig. 2 . Of the 18 tested, one showed significant migration inhibition with EF.
Effects of autologous serum
The effects of autologous serum included (28) 2 (28) 3 (37) 3 (37) 4 (44) 2 (22) 1(25) 0 11(32) 1 (5) 7 (20) 1 (5) Autologous serum from 34 individuals with various non-malignant conditions blocked EF-mediated migration inhibition in 4/11 patients showing significant migration inhibition with EF (Table IV) . Serum-blocking activity in this group occurred in 2 patients with Parkinson's disease, one patient with warts and one with systemic lupus erythematosus. Autologous serum from healthy individuals produced no significant change in macrophage migration from that in the absence of autlogous serum (Table IV) .
Effects of homologous serum
Serum from a healthy individual, 2 patients with carcinoma of the lung (one with and one without autologous blocking activity) and 2 patients with carcinoma of the breast (one with and one without autologous blocking activity) were tested against lymphocytes from 4 patients with carcinoma of the breast, 3 with carcinoma of the lung, 2 with carcinoma of the bladder, 1 with carcinoma of the larynx and 1 with a basal-cell carcinoma of the scalp, for evidence of blocking activity by homologous serum. The results are shown in Table V. Of the 11 cancer patients with the MMI test in the absence of serum, 8 showed significant migration inhibition with EF. In the presence of normal serum, all 8 retained significant migration inhibition with EF. When serum from a patient with carcinoma of the lung without autologous blocking activity was used, all 8 patients retained demonstrable sensitivity. However, serum from a carcinoma of the lung with autologous blocking activity abolished EF-mediated migration inhibition in all 8 patients, regardless of the tumour type from which the lymphocytes under test were derived (Table V) . Serum from a carcinoma of the breast without autologous blocking activity abolished EF-mediated migration inhibition in one patient with a carcinoma of the lung, whilst serum from a carcinoma of the breast with autologous blocking activity abolished EF-mediated migration inhibition in 6/8 sensitized individuals.
DISCUSSION
The results of the present study for lymphocyte sensitivity to EF in malignant and non-malignant disease agree well with those of other workers using the same techniques Light et al., 1975; Singer et al., 1975) . However, the observed frequency of sensitivity in cancer is lower with the MMI test than in the results reported for the MEM test (Field and Caspary, 1970; Caspary and Field, 1971) . This may reflect differences in sensitivity between the two techniques, and this has been discussed previously (Hughes and Paty, 1971, Shelton et al., 1975) . The frequency of sensitivity to EF in the present study was similar in all 3 clinical stages of cancer, and it is thus not possible to discriminate between patients with small primary tumours and extensive metastatic disease by the MMI test. However, Field and Caspary (1972) found a lower degree of lymphocyte sensitivity to CaBP in patients with advanced malignant disease, using a standard number of lymphocytes in the MEM test. This effect was abolished by increasing the number of lymphocytes under test 5-or 10-fold. Thus the inability of the MMI test to discriminate between early and advanced malignant disease may be due to the greater number of lymphocytes routinely used in the test (2 0 X 106 lymphocytes as opposed to 0.5 x 106 in the MEM test).
The present study has also confirmed the findings of Shelton et al. (1975) that sensitivity to EF also occurs in a number of individuals with non-malignant conditions. The high level of sensitization seen in this study in patients with neurological conditions suggests that conditions that might involve nervous parenchymal destruction, result in the release of the EF molecule from the intraperiod line of lamellar myelin (Dickinson et al., 1970) and subsequent sensitization. Alternatively, EF sensitivity may prove to be a primary factor in some disease processes. For instance, the histological appearance of the lesions found in the central nervous system of patients with multiple sclerosis suggests an active immunological process (Nilsson, 1972) . Indeed it may be that a proportion of the carcinomatous neuropathies, sometimes associated with demvelination (Schlaepfer, 1974) observed in a small number of cancer patients, may be a secondary pathological process brought about by the generation of autoaggressive lymphocytes by neoantigen(s) on the tumour-cell surface and immunologically cross-reactive with EF or an EFlike molecule in the central nervous system.
Abolition of EF-mediated migration inhibition by autologous serum was seen in a large proportion of the cancer patients studied, and occurred with a similar frequency in all 3 clinical stages. Moreover, serum which abolished the lymphocyte response to EF in the autologous situation also abolished the EF response of lymphocytes from patients with different tumour types. Serum abolition of the lymphocyte response to EF was also seen in 4/11 sensitized individuals with non-malignant conditions. This serum effect thus differs markedly from serum blocking phenomena observed in cancer patients and thought to be mediated by free circulating antigen or antigen-antibody complexes (Currie and Basham, 1972; Currie, 1973; Sj6gren et al., 1971) . Here, serum blocking activity correlates well with the extent of the disease (Currie, 1973; Bray and Holt, 1975 ) the highest titres being found in advanced disease, and also proves to be specific for the tumour type from which the serum was derived . It seems likely that the serum effect seen in the present study might be closely akin to the serum lymphocyte-depressive factor described by Field and Caspary (1972) and thought to be due to the alpha2 macroglobulin component of serum (Ford, Caspary and Shenton, 1973 ).
In conclusion, it thus seems that the MMI test in its present form, used to measure EF sensitivity and associated serum inhibitory activity, is unable to discriminate between patients with early and advanced malignant disease.
